Literature DB >> 16288380

CD4+ T cell recovery beyond the first year of complete suppression of viral replication during highly active antiretroviral therapy is not influenced by CD8+ T cell activation.

Jose M Benito1, Mariola Lopez, Sara Lozano, Celia Ballesteros, Laura Capa, Pilar Martinez, Juan Gonzalez-Lahoz, Vincent Soriano.   

Abstract

CD38 expression on CD8(+) T cells was longitudinally assessed in 31 human immunodeficiency virus (HIV)-infected persons with undetectable plasma viremia who had undergone highly active antiretroviral therapy (HAART) for 12 months and were followed for a mean of 30 months thereafter. Overall, CD4(+)T cell counts increased during follow-up, whereas CD38 expression remained stable. However, a subset of patients showed declines in CD38 expression, and, conversely, another subset showed increases in CD38 expression. No association could be found between long-term gains in CD4(+) T cells and evolution of CD38 expression. Thus, activation of CD8(+) T cells does not seem to be associated with the extent of CD4(+) T cell recovery beyond the first year of successful HAART.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16288380     DOI: 10.1086/498168

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

Review 1.  Role of immune activation in HIV pathogenesis.

Authors:  Peter W Hunt
Journal:  Curr HIV/AIDS Rep       Date:  2007-02       Impact factor: 5.071

2.  Elevated CD8 counts during HAART are associated with HIV virologic treatment failure.

Authors:  Elizabeth M Krantz; Katherine Huppler Hullsiek; Jason F Okulicz; Amy C Weintrob; Brian K Agan; Nancy F Crum-Cianflone; Anuradha Ganesan; Tomas M Ferguson; Braden R Hale
Journal:  J Acquir Immune Defic Syndr       Date:  2011-08-15       Impact factor: 3.731

3.  Early changes in T-cell activation predict antiretroviral success in salvage therapy of HIV infection.

Authors:  Brett D Shepard; Mona R Loutfy; Janet Raboud; Frank Mandy; Colin M Kovacs; Christina Diong; Michele Bergeron; Victoria Govan; Stacey A Rizza; Jonathan B Angel; Andrew D Badley
Journal:  J Acquir Immune Defic Syndr       Date:  2008-06-01       Impact factor: 3.731

4.  Factors associated with CD8+ T-cell activation in HIV-1-infected patients on long-term antiretroviral therapy.

Authors:  Lu Zheng; Babafemi Taiwo; Rajesh T Gandhi; Peter W Hunt; Ann C Collier; Charles Flexner; Ronald J Bosch
Journal:  J Acquir Immune Defic Syndr       Date:  2014-10-01       Impact factor: 3.731

5.  Interferon-α is the primary plasma type-I IFN in HIV-1 infection and correlates with immune activation and disease markers.

Authors:  Gareth A D Hardy; Scott Sieg; Benigno Rodriguez; Donald Anthony; Robert Asaad; Wei Jiang; Joseph Mudd; Timothy Schacker; Nicholas T Funderburg; Heather A Pilch-Cooper; Robert Debernardo; Ronald L Rabin; Michael M Lederman; Clifford V Harding
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

6.  High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort.

Authors:  Damalie Nakanjako; Isaac Ssewanyana; Harriet Mayanja-Kizza; Agnes Kiragga; Robert Colebunders; Yukari C Manabe; Rose Nabatanzi; Moses R Kamya; Huyen Cao
Journal:  BMC Infect Dis       Date:  2011-02-08       Impact factor: 3.090

Review 7.  Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions.

Authors:  Julie C Gaardbo; Hans J Hartling; Jan Gerstoft; Susanne D Nielsen
Journal:  Clin Dev Immunol       Date:  2012-03-14

8.  Systemic Cytokine Levels Do Not Predict CD4(+) T-Cell Recovery After Suppressive Combination Antiretroviral Therapy in Chronic Human Immunodeficiency Virus Infection.

Authors:  Philip J Norris; Jinbing Zhang; Andrew Worlock; Sangeetha V Nair; Kathryn Anastos; Howard L Minkoff; Maria C Villacres; Mary Young; Ruth M Greenblatt; Seema Desai; Alan L Landay; Stephen J Gange; C Thomas Nugent; Elizabeth T Golub; Sheila M Keating
Journal:  Open Forum Infect Dis       Date:  2016-02-08       Impact factor: 3.835

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.